TIGIT Assay Portfolio Service
Creative Biolabs offers a specialized T cell immunoglobulin and ITIM domain (TIGIT) assay portfolio service to support targeted cancer therapy and diagnosis. We utilize advanced technologies and expert analysis to precisely assess TIGIT. As an emerging immune checkpoint, TIGIT plays a critical role in limiting both adaptive and innate immunity. Our service provides the essential functional and quantitative data needed to understand TIGIT 's mechanism and accelerate the development of novel TIGIT-targeting immunotherapies.
Background What We Can Offer Publication Why Choose Us FAQs Customer Review Related Services Contact Us
The Science: Why TIGIT Assays Are Critical
TIGIT, a receptor belonging to the Ig superfamily, is expressed on activated T cells and NK cells. It has three ligands: CD155, CD112, and CD113. TIGIT inhibits innate and adaptive immunity through multiple mechanisms, including directly inhibiting T cells, indirectly inhibiting T cells by inducing IL-10 production, and impeding CD226-mediated T-cell activation. TIGIT blockade has shown promise in cancer immunotherapy. When combined with PD-1/PD-L1 blockade, it enhances the function of antitumor CD8+ T cells, leading to tumor rejection and prolonged survival.
Fig.1 Determinants of TIGIT expression in the immune microenvironment. 1, 3
Creative Biolabs' TIGIT Assay Portfolio Service
Our comprehensive portfolio provides a range of standardized and customizable solutions, built to meet the diverse needs of our clients.
TIGIT-Ligand Binding Assays
We use platforms like surface plasmon resonance (SPR) and bio-layer interferometry (BLI) to measure the binding affinity of your TIGIT-targeting antibody or protein to TIGIT or its ligands.
TIGIT Reporter Assays
These high-throughput assays use reporter cell lines to screen for agonists or antagonists of the TIGIT signaling pathway, helping to rapidly identify lead drug candidates that can either block the TIGIT-CD155 interaction or activate the TIGIT pathway.
Cell-based TIGIT Functional Assays
These assays evaluate the functional impact of your therapeutic on immune cells by measuring the downstream effects of TIGIT inhibition, including T-cell activation, cytokine production, and enhanced cytotoxicity against tumor cells.
Partner with Creative Biolabs to unlock the full potential of TIGIT-targeting therapies.
Publication
This review explores TIGIT as a promising novel immune checkpoint target for melanoma immunotherapy. The authors highlight that TIGIT, an inhibitory receptor on T cells, NK cells, and Tregs, is a key regulator of both innate and adaptive immunity. The review details TIGIT's role in promoting immunosuppression through multiple mechanisms, including direct inhibition of T and NK cells, suppression of CD226 signaling, and enhancement of Treg function. Clinical and preclinical evidence suggests that TIGIT blockade, especially in combination with other immunotherapies, can enhance antitumor immunity in melanoma. The article concludes that targeting TIGIT offers a promising strategic direction for improving outcomes in melanoma patients.
Fig.2 The multifaceted inhibitory mechanisms of TIGIT in innate and adaptive immunity. 2, 3
Why Choose Us?
With decades of scientific expertise and a commitment to customization and flexibility, Creative Biolabs provides unparalleled scientific consultation. Their state-of-the-art screening platforms offer high-throughput capabilities, enabling the rapid analysis of large compound libraries. By leveraging their TIGIT assay portfolio, clients can gain a clear understanding of their drug candidate's mechanism of action and accelerate its progression toward application. The promising synergy of TIGIT blockade with PD-1/PD-L1 inhibitors makes a comprehensive TIGIT assay portfolio even more critical for drug development, offering new hope for cancer patients.
To discuss your specific project and learn how Creative Biolabs can add value, we encourage you to experience the Creative Biolabs' advantage - Get a Quote Today.
FAQs
Q1: Can you help us with TIGIT blockade in combination with PD-1/PD-L1?
A1: Absolutely. Our functional assays are specifically designed to evaluate the synergistic effects of dual blockade. We can perform co-culture assays with T cells and tumor cells to precisely measure the enhanced anti-tumor response when TIGIT inhibition is combined with PD-1/PD-L1 blockade.
Q2: Is your TIGIT assay portfolio suitable for both early-stage and later-stage drug development
A2: Yes. Our portfolio offers a scalable solution. For early-stage discovery, we have high-throughput screening assays. For later-stage projects, we provide customized, in-depth functional assays to support pre-clinical and regulatory submissions.
Q3: How do your services handle different TIGIT variants or ligands
A3: Creative Biolabs has extensive experience with various TIGIT variants and ligands, including human and murine TIGIT, CD155, and CD112. We can express and purify these proteins to create customized assay systems that precisely match your specific project requirements.
Customer Review
-
Proven Functional Efficacy
We successfully demonstrated the functional efficacy of our lead compound with a high degree of confidence. Using Creative Biolabs' TIGIT reporter assays in our research has significantly improved our ability to rapidly screen and validate our drug candidates. - J***na N
-
Precise Binding Kinetics Data
The binding kinetics data we received were incredibly precise, allowing us to differentiate between several promising antibodies. Their SPR service provided a level of detail we couldn't achieve in-house. - M**in L
Related Services
Cancer Immune Combination Therapy Development Services
Creative Biolabs provides personalized cancer immune combination therapy development services. Our approach leads to custom therapy regimens suitable for specific genetic profiles, which can improve patient outcomes and reduce the likelihood of cancer recurrence.
Learn More →
Immune Checkpoint Assay Service
Creative Biolabs offers novel cell-based assays to assess the mechanism of action (MoA) of antibodies. We can quantitatively and effectively evaluate both co-inhibitory and co-stimulatory pathways, which are essential for immune regulation.
Learn More →
Contact Us
Creative Biolabs offers an unparalleled TIGIT assay portfolio, providing the expertise, technology, and flexibility to accelerate your immuno-oncology drug development. We are committed to helping you navigate the complexities of the TIGIT pathway and achieve your research goals.
Contact Our Team for More Information and to Discuss Your Project.
References
-
Zhang, Peng, et al. "Targeting TIGIT for cancer immunotherapy: recent advances and future directions." Biomarker Research 12.1 (2024): 7. https://doi.org/10.1186/s40364-023-00543-z
-
Tang, Wei, et al. "TIGIT, a novel immune checkpoint therapy for melanoma." Cell Death & Disease 14.7 (2023): 466. https://doi.org/10.1038/s41419-023-05961-3
-
Distributed under Open Access license CC BY 4.0, without modification.
